Developer docs
API playgroundTry for free, no card

Search company profiles

Wellthy Therapeutics

Full company profile

uuid0005l2v

Namestring
Wellthy Therapeutics
Legal namestring
Wellthy Therapeutics Private Limited
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Wellthy Therapeutics is a Mumbai-headquartered digital therapeutics company that builds and commercializes the wellthy CARE™ platform, a globally regulated, cloud-based Software-as-a-Medical-Device (SaMD) operating system for chronic disease management. The platform combines AI/ML-powered personalization with Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) led digital interventions, remote patient monitoring via connected medical devices (glucometers, BP monitors), and human health-coach touchpoints in a 'phygital' care model, covering 8 therapeutic areas including Type 2 Diabetes, Hypertension, Dyslipidemia, Congestive Heart Failure, Ischemic Heart Disease, Clinical Obesity, Chronic Kidney Disease, and Asthma.

The platform is supported by an unusually comprehensive regulatory and quality stack — CE Mark (Class 1 under EU MDR 2017/745), ISO 13485:2016, ISO 14971:2019, ISO 27001:2013, ISO 27701:2019, IEC 62304:2006, GDPR, CDSCO registration, FDA CFR Part 11 and Part 820, and HIPAA — enabling Wellthy to act as manufacturer-of-record for global life science partners and to deliver culturally localized content across Indian regional languages (Hindi, Kannada) and international markets. The company's clinical credibility is anchored in 20–30+ peer-reviewed publications across JMIR, ADA, ACC, IDF, ATTD, and ADCES, and demonstrated outcomes including 1.1% absolute HbA1C reduction, 90% medication adherence uplift, 85% pain reduction in rheumatoid arthritis, 61% cholesterol reduction, and a 98% successful pregnancy delivery rate.

Wellthy serves pharmaceutical, insurance, and medical device enterprises — including Roche Diabetes Care, Cipla, Pfizer, Abbott, ResMed, Bayer G4A, Ferrer, Intas, Manipal Cigna, Aviva, Swiss Re, RGA, and DHFL Pramerica — through platform licensing, co-development of companion SaMD products, standalone DTx products, and digital health advisory services. It also operates a direct-to-consumer wellthy CARE app with 100,000+ downloads (4.6/5 rating) used primarily as a patient engagement and real-world evidence layer. The company expanded into the US (May 2023) and Japan (June 2023), and was acquired by TruDoc in February 2024 to accelerate digital health delivery across the GCC region and India.

Short descriptiontext

Wellthy Therapeutics builds the globally regulated, AI-powered wellthy CARE™ digital therapeutics platform, delivering companion SaMD and standalone CBT/ACT-based programs across 8 therapeutic areas to pharmaceutical, insurance, and medical device partners including Roche, Pfizer, Abbott, Cipla, and Manipal Cigna.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMumbai, India
HQ citystring
Mumbai
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital therapeutics platform, chronic disease management, software as medical device, behavioral health interventions, patient support programs
Industry5 codes
PRIMARYHLACANAO
DTx/SaMD Deployment, Integration & Reimbursement Enablement
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACANAH
Therapeutic Companion Apps (Drug-Device-Digital Combination)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAK
Women’s Health & Fertility Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code2 codes
  • Custom Computer Programming Services541511
  • Ambulatory Health Care Services621
SIC code2 codes
  • Services-Computer Programming, Data Processing, Etc.7370
  • Services-Health Services8000
Product category
Digital Therapeutics Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Platform Licensing to Life Science Partners
TypeSubscription Recurring
Description

Wellthy licenses its wellthy CARE platform to pharmaceutical companies, medical device manufacturers, insurers, and healthcare systems. Partners use the platform to build and deploy digital therapeutic solutions for their patients and customers. Revenue is generated through licensing fees, platform access fees, and co-development costs. This is the primary revenue stream.

wellthytherapeutics.com
2Digital Health Advisory and Consulting Services
TypeProfessional Services
Description

Wellthy provides end-to-end consulting services to life science companies looking to build SaMD solutions in-house. Services span discovery, design, clinical development, regulatory navigation, and commercialization support. Revenue is generated through project-based consulting engagements.

wellthytherapeutics.com
3Companion SaMD and Standalone DTx Products
TypeLicensing Royalties
Description

Wellthy develops and commercializes both companion Software as a Medical Device (SaMD) products used in combination with drugs or devices, and standalone digital therapeutics prescribed for unmet patient needs. Revenue from these products may flow through pharmaceutical co-promotion, payer reimbursement, or direct B2B2C models.

wellthytherapeutics.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Wellthy CARE
Description

Digital care platform and operating system for digital therapeutic solutions

wellthytherapeutics.com
Core offering1 text field

Wellthy Therapeutics licenses its wellthy CARE platform — a globally regulated, AI/ML-powered digital therapeutics operating system — to pharmaceutical, insurance, medical device, and healthcare system partners. Partners use the modular DTx/SaMD platform to build, deploy, and commercialize companion Software as a Medical Device solutions, standalone digital therapeutics, patient support programs, and remote patient monitoring products for chronic disease management across 8 therapeutic areas. The company also provides digital health advisory services covering SaMD discovery, clinical development, regulatory navigation, and commercialization support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 13 values shown
  • 85% reduction in pain for RA (rheumatoid arthritis) patients
+12 more records
Product overview1 text field

Wellthy Therapeutics offers a platform-plus-modules architecture centered on the wellthy CARE™ platform, a globally regulated DTx operating system. The core platform enables biopharma, med device, insurance, and healthcare system partners to build and deploy Software as a Medical Device (SaMD) solutions. Key product modules include Companion SaMD, Standalone DTx (CBT/ACT-based), Patient Support Programs, and Remote Patient Monitoring capabilities. Additional services include Digital Health Advisory consulting for regulatory and development support.

Product and service6 records
1wellthy CARE Platform
CategoryDigital therapeutics platform
Description

A globally regulated, modular, cloud-based DTx/SaMD operating system that serves as the foundation for building companion Software as a Medical Device solutions, standalone digital therapeutics, patient support programs, and remote patient monitoring for pharmaceutical, insurance, medical device, and healthcare system partners. Features AI/ML-powered personalization, CBT/ACT-led behavioral interventions, and multilingual therapy delivery across multiple therapeutic areas including Type 2 Diabetes, Hypertension, Dyslipidemia, Congestive Heart Failure, Ischemic Heart Disease, Clinical Obesity, Chronic Kidney Disease, and Asthma.

2Companion SaMD
CategoryCompanion software as medical device
Description

Clinically validated Software as a Medical Device solutions built to be used in combination with drug therapy or medical devices to improve the real-world effectiveness, adherence, and outcomes of those existing treatments. Targeted at pharmaceutical and medical device companies seeking to augment their products with companion digital therapeutics.

3Standalone DTx
CategoryStandalone digital therapeutics
Description

Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) led digital therapeutics that can be prescribed standalone to address unmet patient needs for specific chronic conditions. Marketed to pharmaceutical, insurance, and healthcare system partners for prescription to patient populations with complex clinical needs.

4Patient Support Programs
CategoryPatient support programs
Description

Digital therapy-led patient support programs for pharmaceutical and life science partners that track and monitor digital biomarkers, improve patient engagement, medication adherence, and outcomes across chronic disease management. Designed to be deployed as embedded programs within pharma Patient Support Programs and insurance customer engagement initiatives.

5Remote Patient Monitoring
CategoryRemote patient monitoring
Description

Solutions to remotely monitor patient progress through continual patient-reported and connected device-driven data streams (integrating with glucometers, BP monitors, and other medical devices), enabling personalized just-in-time interventions and clinical decision support for healthcare providers and life science partners.

6Digital Health Advisory Services
CategoryDigital health consulting
Description

End-to-end consulting services for life science companies looking to build SaMD solutions in-house, spanning discovery, design, clinical development, regulatory navigation, evidence generation, and commercialization support. Delivered through project-based engagements with pharmaceutical, medical device, and insurance partners.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-02-13
Description

TruDoc acquired Wellthy Therapeutics in February 2024 to deliver premier digital health services in the GCC (Gulf Cooperation Council) region and expand into India. The acquisition combines TruDoc's existing digital health capabilities with Wellthy's DTx platform, evidence base, and Asian market expertise to create a comprehensive digital health provider across MENA and India.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-02-27
Description

Spanish pharmaceutical leader Ferrer partnered with Wellthy Therapeutics for digital therapeutic solutions. The partnership focused on co-creating patient support programs leveraging Wellthy's clinically validated DTx platform to improve patient outcomes across Ferrer's therapeutic areas.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-03-07
Description

Bayer G4A selected Wellthy Therapeutics as a partner for digital health innovation, recognizing Wellthy's platform capabilities in chronic disease management and DTx solution development for unmet patient needs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-02-21
Description

Cipla partnered with Wellthy Therapeutics to offer digital therapeutics for diabetes and cardiovascular diseases, augmenting Cipla's product portfolio with digital health software for improved medication management and patient monitoring.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-11-28
Description

Roche Diabetes Care India partnered with Wellthy Therapeutics to offer an AI-based digital diabetes coaching solution for Accu-Chek Active glucometer users. The partnership combined Roche's device ecosystem with Wellthy's DTx platform to address clinical inertia and improve patient outcomes. Results demonstrated 130% increase in blood glucose monitoring frequency and reduced glucose variability among enrolled patients.

6Wockhardt Hospital SOBO
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-11-21
Description

Wockhardt Hospital in South Mumbai launched a diabetes clinic powered by Wellthy Therapeutics in November 2018, integrating digital therapeutic solutions into the hospital's chronic disease management program for diabetes patients.

wellthytherapeutics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-08-10
Description

Global reinsurance leader Swiss Re engaged with Wellthy Therapeutics through its 2017 InsurTech Accelerator program, exploring digital health integration for insurance risk management and product innovation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pfizer is listed as a partner on Wellthy's platform page. The nature of the partnership involves combining Pfizer's pharmaceutical products with Wellthy's digital therapeutic platform to improve patient outcomes and engagement.

9Abbott
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Abbott is listed as a partner on Wellthy's platform page. The partnership leverages Wellthy's DTx platform with Abbott's healthcare products to deliver integrated patient care solutions.

wellthytherapeutics.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ResMed partnered with Wellthy Therapeutics as part of the medical devices partnership ecosystem. The collaboration focuses on DTx-based solutions to enhance medical device adherence and boost patient lifetime value through improved therapy outcomes.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Intas Pharmaceuticals is listed as a partner on Wellthy's platform page, indicating collaboration on digital therapeutic solutions for chronic disease management.

12Manipal Cigna
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Manipal Cigna partnered with Wellthy Therapeutics for health insurance digital care integration. The partnership delivers evidence-based remote care for chronic insured patients, demonstrating significant BP and blood sugar reduction outcomes. Wellthy's platform enabled the insurer to engage chronic disease patients and balance risk through improved health outcomes.

wellthytherapeutics.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Aviva partnered with Wellthy Therapeutics to integrate digital therapeutics into insurance products, aiming to develop healthier insured patient cohorts and offer innovative insurance products with value-based care components.

14RGA
Strategic tierCoreTypeStrategic or Co-development Partner
Description

RGA (Reinsurance Group of America), a leading reinsurance company, partnered with Wellthy Therapeutics as part of its digital health ecosystem, exploring integration of DTx solutions into reinsurance products for improved risk assessment and patient outcomes.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

DHFL Pramerica Life Insurance Company partnered with Wellthy Therapeutics to enable evidence-based remote care for chronic insured patients. Wellthy's digital therapeutic platform was used to provide protocol-driven virtual care pathways during the COVID-19 pandemic, helping reduce exposure risk while maintaining care continuity for chronic disease patients.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US digital health company delivering virtual care programs for chronic conditions (diabetes, hypertension, obesity) with a B2B distribution model targeting employers, insurers, and health systems. Closely comparable to Wellthy in B2B chronic-disease digital therapeutic delivery and outcomes-based contracting.

TypeDirect peer
Description

Digital chronic condition management platform integrating connected devices (glucometers, BP monitors) with AI-driven coaching, sold to employers, health plans, and pharma. Comparable to Wellthy on device-integration, multi-therapeutic-area coverage, and B2B2C distribution.

TypeDirect peer
Description

Digital therapeutics company historically focused on SaMD for oncology, diabetes, and hemophilia, with deep pharmaceutical and medical-device partnerships. Comparable to Wellthy on the SaMD platform play and enterprise biopharma business model.

4Better Therapeutics
TypeDirect peer
Description

Prescription digital therapeutics company developing FDA-regulated software for cardiometabolic conditions including type 2 diabetes and hypertension. Highly comparable to Wellthy on the condition-specific DTx positioning and regulatory clearance pathway.

TypeBroad incumbent
Description

Large-scale digital MSK and chronic pain care platform combining wearable sensors, AI, and human coaching distributed through employers and health plans. Comparable to Wellthy in the broader phygital digital care model and enterprise payer distribution, but at materially larger scale and on a different therapeutic area.

6Noom Health
TypeDirect peer
Description

Digital health platform combining AI-driven behavioral coaching with CBT-inspired interventions for chronic disease and weight management. Comparable to Wellthy on the behavioral-science-led intervention design and enterprise/insurer distribution model.

TypeDirect peer
Description

Digital chronic disease management platform (now part of Teladoc Health) combining connected devices, AI coaching, and behavioral science. Comparable to Wellthy on the device-integration plus CBT-style coaching model across diabetes, hypertension, and cardiometabolic conditions.

TypeDirect peer
Description

Digital therapeutic platform for respiratory conditions combining connected inhaler sensors, patient engagement, and clinical decision support, now part of ResMed. Comparable to Wellthy on the connected-device-plus-DTx model and medical-device partnership channel (Wellthy already partners with ResMed).

TypeDirect peer
Description

Digital therapeutics company with FDA-cleared cognitive therapy products and a B2B2C distribution model via pharma, payers, and providers. Comparable to Wellthy on the regulated software-as-medicine positioning and enterprise sales motion.

10Pear Therapeutics
TypeDirect peer
Description

Pioneer in prescription digital therapeutics with FDA-cleared PDT products in substance use disorder, insomnia, and ADHD. Comparable to Wellthy on regulated DTx platform positioning and behavioral-science-led therapy design.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers13 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance11 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Wellthy Therapeutics

Digital Therapeutics Softwarewellthytherapeutics.com

Wellthy Therapeutics builds the globally regulated, AI-powered wellthy CARE™ digital therapeutics platform, delivering companion SaMD and standalone CBT/ACT-based programs across 8 therapeutic areas to pharmaceutical, insurance, and medical device partners including Roche, Pfizer, Abbott, Cipla, and Manipal Cigna.

What Wellthy Therapeutics does

Wellthy Therapeutics is a Mumbai-headquartered digital therapeutics company that builds and commercializes the wellthy CARE™ platform, a globally regulated, cloud-based Software-as-a-Medical-Device (SaMD) operating system for chronic disease management. The platform combines AI/ML-powered personalization with Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) led digital interventions, remote patient monitoring via connected medical devices (glucometers, BP monitors), and human health-coach touchpoints in a 'phygital' care model, covering 8 therapeutic areas including Type 2 Diabetes, Hypertension, Dyslipidemia, Congestive Heart Failure, Ischemic Heart Disease, Clinical Obesity, Chronic Kidney Disease, and Asthma.

The platform is supported by an unusually comprehensive regulatory and quality stack — CE Mark (Class 1 under EU MDR 2017/745), ISO 13485:2016, ISO 14971:2019, ISO 27001:2013, ISO 27701:2019, IEC 62304:2006, GDPR, CDSCO registration, FDA CFR Part 11 and Part 820, and HIPAA — enabling Wellthy to act as manufacturer-of-record for global life science partners and to deliver culturally localized content across Indian regional languages (Hindi, Kannada) and international markets. The company's clinical credibility is anchored in 20–30+ peer-reviewed publications across JMIR, ADA, ACC, IDF, ATTD, and ADCES, and demonstrated outcomes including 1.1% absolute HbA1C reduction, 90% medication adherence uplift, 85% pain reduction in rheumatoid arthritis, 61% cholesterol reduction, and a 98% successful pregnancy delivery rate.

Wellthy serves pharmaceutical, insurance, and medical device enterprises — including Roche Diabetes Care, Cipla, Pfizer, Abbott, ResMed, Bayer G4A, Ferrer, Intas, Manipal Cigna, Aviva, Swiss Re, RGA, and DHFL Pramerica — through platform licensing, co-development of companion SaMD products, standalone DTx products, and digital health advisory services. It also operates a direct-to-consumer wellthy CARE app with 100,000+ downloads (4.6/5 rating) used primarily as a patient engagement and real-world evidence layer. The company expanded into the US (May 2023) and Japan (June 2023), and was acquired by TruDoc in February 2024 to accelerate digital health delivery across the GCC region and India.

Wellthy Therapeutics firmographics

Firmographics
Name
Wellthy Therapeutics
Legal name
Wellthy Therapeutics Private Limited
Website
https://wellthytherapeutics.com
Company type
Private
Founded year
2017
Operating status
Acquired
Headcount range
51–100 employees
Short description
Wellthy Therapeutics builds the globally regulated, AI-powered wellthy CARE™ digital therapeutics platform, delivering companion SaMD and standalone CBT/ACT-based programs across 8 therapeutic areas to pharmaceutical, insurance, and medical device partners including Roche, Pfizer, Abbott, Cipla, and Manipal Cigna.
Ownership category
akta.pro rank

Wellthy Therapeutics industry classification

Industry
Product category
Digital Therapeutics Software
NAICS
Custom Computer Programming Services (541511), Ambulatory Health Care Services (621)
SIC
Services-Computer Programming, Data Processing, Etc. (7370), Services-Health Services (8000)
akta.pro industry
PRIMARYHLACANAO
DTx/SaMD Deployment, Integration & Reimbursement Enablement
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACANAH
Therapeutic Companion Apps (Drug-Device-Digital Combination)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAK
Women’s Health & Fertility Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Digital therapeutics platform
  • Chronic disease management
  • Software as medical device
  • Behavioral health interventions
  • Patient support programs

Where Wellthy Therapeutics is headquartered

Location

Headquarters

HQ city
Mumbai
HQ country
India
HQ region
Asia

Offices1 record

Markets served

Wellthy Therapeutics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Platform Licensing to Life Science Partners: Wellthy licenses its wellthy CARE platform to pharmaceutical companies, medical device manufacturers, insurers, and healthcare systems. Partners use the platform to build and deploy digital therapeutic solutions for their patients and customers. Revenue is generated through licensing fees, platform access fees, and co-development costs. This is the primary revenue stream.
  2. Digital Health Advisory and Consulting Services: Wellthy provides end-to-end consulting services to life science companies looking to build SaMD solutions in-house. Services span discovery, design, clinical development, regulatory navigation, and commercialization support. Revenue is generated through project-based consulting engagements.
  3. Companion SaMD and Standalone DTx Products: Wellthy develops and commercializes both companion Software as a Medical Device (SaMD) products used in combination with drugs or devices, and standalone digital therapeutics prescribed for unmet patient needs. Revenue from these products may flow through pharmaceutical co-promotion, payer reimbursement, or direct B2B2C models.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels10 records

Wellthy Therapeutics product offering

Product offering

Core offering

Wellthy Therapeutics licenses its wellthy CARE platform — a globally regulated, AI/ML-powered digital therapeutics operating system — to pharmaceutical, insurance, medical device, and healthcare system partners. Partners use the modular DTx/SaMD platform to build, deploy, and commercialize companion Software as a Medical Device solutions, standalone digital therapeutics, patient support programs, and remote patient monitoring products for chronic disease management across 8 therapeutic areas. The company also provides digital health advisory services covering SaMD discovery, clinical development, regulatory navigation, and commercialization support.

Product overview

Wellthy Therapeutics offers a platform-plus-modules architecture centered on the wellthy CARE™ platform, a globally regulated DTx operating system. The core platform enables biopharma, med device, insurance, and healthcare system partners to build and deploy Software as a Medical Device (SaMD) solutions. Key product modules include Companion SaMD, Standalone DTx (CBT/ACT-based), Patient Support Programs, and Remote Patient Monitoring capabilities. Additional services include Digital Health Advisory consulting for regulatory and development support.

Differentiator

Problem solved

Functional benefit

Brands

  • Wellthy CARE: Digital care platform and operating system for digital therapeutic solutions

Products and services

  • wellthy CARE Platform A globally regulated, modular, cloud-based DTx/SaMD operating system that serves as the foundation for building companion Software as a Medical Device solutions, standalone digital therapeutics, patient support programs, and remote patient monitoring for pharmaceutical, insurance, medical device, and healthcare system partners. Features AI/ML-powered personalization, CBT/ACT-led behavioral interventions, and multilingual therapy delivery across multiple therapeutic areas including Type 2 Diabetes, Hypertension, Dyslipidemia, Congestive Heart Failure, Ischemic Heart Disease, Clinical Obesity, Chronic Kidney Disease, and Asthma.
  • Companion SaMD Clinically validated Software as a Medical Device solutions built to be used in combination with drug therapy or medical devices to improve the real-world effectiveness, adherence, and outcomes of those existing treatments. Targeted at pharmaceutical and medical device companies seeking to augment their products with companion digital therapeutics.
  • Standalone DTx Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) led digital therapeutics that can be prescribed standalone to address unmet patient needs for specific chronic conditions. Marketed to pharmaceutical, insurance, and healthcare system partners for prescription to patient populations with complex clinical needs.
  • Patient Support Programs Digital therapy-led patient support programs for pharmaceutical and life science partners that track and monitor digital biomarkers, improve patient engagement, medication adherence, and outcomes across chronic disease management. Designed to be deployed as embedded programs within pharma Patient Support Programs and insurance customer engagement initiatives.
  • Remote Patient Monitoring Solutions to remotely monitor patient progress through continual patient-reported and connected device-driven data streams (integrating with glucometers, BP monitors, and other medical devices), enabling personalized just-in-time interventions and clinical decision support for healthcare providers and life science partners.
  • Digital Health Advisory Services End-to-end consulting services for life science companies looking to build SaMD solutions in-house, spanning discovery, design, clinical development, regulatory navigation, evidence generation, and commercialization support. Delivered through project-based engagements with pharmaceutical, medical device, and insurance partners.

Quantifiable outcome

  • 85% reduction in pain for RA (rheumatoid arthritis) patients
  • +12 more outcomes

Companies that use Wellthy Therapeutics

Customer profile

Named customers13 records

Segments4 records

Ideal customer profiles4 records

Wellthy Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability5 records

Feature6 records

Wellthy Therapeutics partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered flagship and core.

  • TruDocflagshipStrategic or Co-development Partner · 13 February 2024TruDoc acquired Wellthy Therapeutics in February 2024 to deliver premier digital health services in the GCC (Gulf Cooperation Council) region and expand into India. The acquisition combines TruDoc's existing digital health capabilities with Wellthy's DTx platform, evidence base, and Asian market expertise to create a comprehensive digital health provider across MENA and India.
  • Ferrer (Spain)coreStrategic or Co-development Partner · 27 February 2020Spanish pharmaceutical leader Ferrer partnered with Wellthy Therapeutics for digital therapeutic solutions. The partnership focused on co-creating patient support programs leveraging Wellthy's clinically validated DTx platform to improve patient outcomes across Ferrer's therapeutic areas.
  • Bayer G4AcoreStrategic or Co-development Partner · 7 March 2019Bayer G4A selected Wellthy Therapeutics as a partner for digital health innovation, recognizing Wellthy's platform capabilities in chronic disease management and DTx solution development for unmet patient needs.
  • CiplacoreStrategic or Co-development Partner · 21 February 2019Cipla partnered with Wellthy Therapeutics to offer digital therapeutics for diabetes and cardiovascular diseases, augmenting Cipla's product portfolio with digital health software for improved medication management and patient monitoring.
  • Roche Diabetes Care IndiacoreStrategic or Co-development Partner · 28 November 2018Roche Diabetes Care India partnered with Wellthy Therapeutics to offer an AI-based digital diabetes coaching solution for Accu-Chek Active glucometer users. The partnership combined Roche's device ecosystem with Wellthy's DTx platform to address clinical inertia and improve patient outcomes. Results demonstrated 130% increase in blood glucose monitoring frequency and reduced glucose variability among enrolled patients.
  • Wockhardt Hospital SOBOcoreStrategic or Co-development Partner · 21 November 2018Wockhardt Hospital in South Mumbai launched a diabetes clinic powered by Wellthy Therapeutics in November 2018, integrating digital therapeutic solutions into the hospital's chronic disease management program for diabetes patients.
  • Swiss RecoreStrategic or Co-development Partner · 10 August 2017Global reinsurance leader Swiss Re engaged with Wellthy Therapeutics through its 2017 InsurTech Accelerator program, exploring digital health integration for insurance risk management and product innovation.
  • PfizercoreStrategic or Co-development PartnerPfizer is listed as a partner on Wellthy's platform page. The nature of the partnership involves combining Pfizer's pharmaceutical products with Wellthy's digital therapeutic platform to improve patient outcomes and engagement.
  • AbbottcoreStrategic or Co-development PartnerAbbott is listed as a partner on Wellthy's platform page. The partnership leverages Wellthy's DTx platform with Abbott's healthcare products to deliver integrated patient care solutions.
  • ResMedcoreStrategic or Co-development PartnerResMed partnered with Wellthy Therapeutics as part of the medical devices partnership ecosystem. The collaboration focuses on DTx-based solutions to enhance medical device adherence and boost patient lifetime value through improved therapy outcomes.
  • Intas PharmaceuticalscoreStrategic or Co-development PartnerIntas Pharmaceuticals is listed as a partner on Wellthy's platform page, indicating collaboration on digital therapeutic solutions for chronic disease management.
  • Manipal CignacoreStrategic or Co-development PartnerManipal Cigna partnered with Wellthy Therapeutics for health insurance digital care integration. The partnership delivers evidence-based remote care for chronic insured patients, demonstrating significant BP and blood sugar reduction outcomes. Wellthy's platform enabled the insurer to engage chronic disease patients and balance risk through improved health outcomes.
  • AvivacoreStrategic or Co-development PartnerAviva partnered with Wellthy Therapeutics to integrate digital therapeutics into insurance products, aiming to develop healthier insured patient cohorts and offer innovative insurance products with value-based care components.
  • RGAcoreStrategic or Co-development PartnerRGA (Reinsurance Group of America), a leading reinsurance company, partnered with Wellthy Therapeutics as part of its digital health ecosystem, exploring integration of DTx solutions into reinsurance products for improved risk assessment and patient outcomes.
  • DHFL Pramerica Life InsurancecoreStrategic or Co-development PartnerDHFL Pramerica Life Insurance Company partnered with Wellthy Therapeutics to enable evidence-based remote care for chronic insured patients. Wellthy's digital therapeutic platform was used to provide protocol-driven virtual care pathways during the COVID-19 pandemic, helping reduce exposure risk while maintaining care continuity for chronic disease patients.

Scale indicators9 records

Recent moves8 records

Expansion highlights7 records

Wellthy Therapeutics competitors and assessment

Company assessment

Direct peers

  • Omada Health: US digital health company delivering virtual care programs for chronic conditions (diabetes, hypertension, obesity) with a B2B distribution model targeting employers, insurers, and health systems. Closely comparable to Wellthy in B2B chronic-disease digital therapeutic delivery and outcomes-based contracting.
  • DarioHealth: Digital chronic condition management platform integrating connected devices (glucometers, BP monitors) with AI-driven coaching, sold to employers, health plans, and pharma. Comparable to Wellthy on device-integration, multi-therapeutic-area coverage, and B2B2C distribution.
  • Voluntis (now part of AptarGroup): Digital therapeutics company historically focused on SaMD for oncology, diabetes, and hemophilia, with deep pharmaceutical and medical-device partnerships. Comparable to Wellthy on the SaMD platform play and enterprise biopharma business model.
  • Better Therapeutics: Prescription digital therapeutics company developing FDA-regulated software for cardiometabolic conditions including type 2 diabetes and hypertension. Highly comparable to Wellthy on the condition-specific DTx positioning and regulatory clearance pathway.
  • Noom Health: Digital health platform combining AI-driven behavioral coaching with CBT-inspired interventions for chronic disease and weight management. Comparable to Wellthy on the behavioral-science-led intervention design and enterprise/insurer distribution model.
  • Livongo (Teladoc Health): Digital chronic disease management platform (now part of Teladoc Health) combining connected devices, AI coaching, and behavioral science. Comparable to Wellthy on the device-integration plus CBT-style coaching model across diabetes, hypertension, and cardiometabolic conditions.
  • Propeller Health (ResMed): Digital therapeutic platform for respiratory conditions combining connected inhaler sensors, patient engagement, and clinical decision support, now part of ResMed. Comparable to Wellthy on the connected-device-plus-DTx model and medical-device partnership channel (Wellthy already partners with ResMed).
  • Akili Interactive: Digital therapeutics company with FDA-cleared cognitive therapy products and a B2B2C distribution model via pharma, payers, and providers. Comparable to Wellthy on the regulated software-as-medicine positioning and enterprise sales motion.
  • Pear Therapeutics: Pioneer in prescription digital therapeutics with FDA-cleared PDT products in substance use disorder, insomnia, and ADHD. Comparable to Wellthy on regulated DTx platform positioning and behavioral-science-led therapy design.

Broad incumbents

  • Hinge Health: Large-scale digital MSK and chronic pain care platform combining wearable sensors, AI, and human coaching distributed through employers and health plans. Comparable to Wellthy in the broader phygital digital care model and enterprise payer distribution, but at materially larger scale and on a different therapeutic area.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Wellthy Therapeutics social profiles

Digital presence

Wellthy Therapeutics compliance and trust

Trust signal

Compliance11 records

Wellthy Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Wellthy Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

Wellthy Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Wellthy Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wellthy Therapeutics

What does Wellthy Therapeutics do?

Wellthy Therapeutics licenses its wellthy CARE platform — a globally regulated, AI/ML-powered digital therapeutics operating system — to pharmaceutical, insurance, medical device, and healthcare system partners. Partners use the modular DTx/SaMD platform to build, deploy, and commercialize companion Software as a Medical Device solutions, standalone digital therapeutics, patient support programs, and remote patient monitoring products for chronic disease management across 8 therapeutic areas. The company also provides digital health advisory services covering SaMD discovery, clinical development, regulatory navigation, and commercialization support.

Is Wellthy Therapeutics a public or private company?

Wellthy Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Wellthy Therapeutics founded?

Wellthy Therapeutics was founded in 2017. It employs 51 to 100 people.

Where is Wellthy Therapeutics based?

Wellthy Therapeutics is headquartered in Mumbai, India, in the Asia region.

How does Wellthy Therapeutics make money?

Three revenue lines are on record. Platform Licensing to Life Science Partners are the primary driver. The others are digital Health Advisory and Consulting Services and companion SaMD and Standalone DTx Products.

Who are Wellthy Therapeutics's main competitors?

Direct peers on record are Omada Health, DarioHealth, Voluntis (now part of AptarGroup), Better Therapeutics, Noom Health, Livongo (Teladoc Health), Propeller Health (ResMed), Akili Interactive and Pear Therapeutics. Hinge Health is listed as a broad incumbent.

Does Wellthy Therapeutics have an API?

No public API is recorded for Wellthy Therapeutics.

What industry is Wellthy Therapeutics in?

Wellthy Therapeutics's product category is Digital Therapeutics Software. Its primary akta.pro industry code is HLACANAO, DTx/SaMD Deployment, Integration & Reimbursement Enablement, with a secondary code of HLACANAM, DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms. Its NAICS code is 541511 and its SIC code is 7370.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
pharmaphorumCipla taps Wellthy for digital therapeutics expertiseIndian pharmaceutical company Cipla has acquired a nearly 12% stake in digital therapeutics startup Wellthy Therapeutics for approximately $1.5 million to collaborate on combined drug and digital therapies for type 2 diabetes and cardiovascular disease. The partnership aims to integrate Wellthy's clinically validated digital management platform with Cipla's brands to provide multi-lingual patient coaching and clinical assistance. This transaction, expected to close before March 10th, represents Cipla's strategic expansion into the digital medicine category.pharmaphorumDigital Innovators: Wellthy Therapeutics' Abhishek ShahAbhishek Shah, CEO of Wellthy Therapeutics, discussed the company's evolution into a platform for deploying regulatory-compliant digital health solutions during an interview at the Frontiers Health conference in Milan. Wellthy has established partnerships with pharma companies across Europe and Asia to address unmet patient needs through its proprietary Wellthy CARE™ DTx platform. The article highlights how forced digitization during the pandemic accelerated changes within the healthcare sector and reinforced the company's customer-centric approach.WellthytherapeuticsFrom Insight to Impact: TruDoc Acquires Wellthy Therapeutics to Deliver Premier Digital Health Services in the GCC and Expand to IndiaTruDoc Healthcare has acquired Wellthy Therapeutics, a digital chronic disease management platform, to expand its digital health services in the GCC and enter the Indian market. This acquisition combines TruDoc's virtual care infrastructure with Wellthy's behavioral science solutions to create an integrated primary care ecosystem aimed at improving patient outcomes and reducing healthcare costs.CoveragerTruDoc acquires Wellthy TherapeuticsTelehealth provider TruDoc has acquired Wellthy Therapeutics, a chronic disease management platform, to expand its strategic footprint into new markets including India. The integration aims to combine digital therapeutic solutions with virtual and in-home healthcare services to enhance patient access and reduce overall healthcare costs.Life Science Company NewsTruDoc acquires Wellthy Therapeutics to deliver digital health services in Gulf and expand to IndiaDubai-based TruDoc Healthcare has acquired Indian health tech startup Wellthy Therapeutics to integrate its digital therapeutic solutions with TruDoc's virtual care services. The combined entity aims to expand operations into India and reinforce TruDoc's position in the Gulf Cooperation Council region while targeting a sustainable healthcare ecosystem impacting 10 million lives.PR NewswireFrom Insight to Impact: TruDoc Acquires Wellthy Therapeutics to Deliver Premier Digital Health Services in the GCC and Expand to IndiaTruDoc Healthcare announced the acquisition of Wellthy Therapeutics on February 13, 2024, to integrate digital therapeutic solutions with its virtual primary care services. This strategic move aims to expand TruDoc's operations into India while reinforcing its market position in the GCC through enhanced patient-centric care and cost reduction initiatives.LatestLYWellthy Therapeutics Announces Expansion into the United States - Completes FDA CFR Part 11, FDA CFR Part 820, and HIPAA Certification for Its PlatformWellthy Therapeutics has completed FDA 21 CFR Part 820, FDA 21 CFR Part 11, and HIPAA certifications for its software-as-a-medical-device platform. This regulatory achievement facilitates the company's expansion into the United States market by ensuring compliance with strict data security and quality standards.GlobeNewswireWellthy Therapeutics Announces Expansion into the United States - Completes FDA CFR Part 11, FDA CFR Part 820, and HIPAA Certification for Its PlatformWellthy Therapeutics, a Mumbai-based digital health and digital therapeutics company, has completed FDA 21 CFR Part 820, FDA 21 CFR Part 11, and HIPAA certifications for its software-as-a-medical-device platform, enabling its expansion into the United States market. The platform, already compliant with EU MDR, ISO 13485, ISO 27001, and GDPR standards, allows pharma companies, healthcare providers, and health plans to configure and launch customized digital health solutions. The company reports that over 150,000 patients have benefited from its platform, which it positions as a cost-effective alternative to traditional digital health product development.PR NewswireWellthy Therapeutics Announces Expansion into the United States - Completes FDA CFR Part 11, FDA CFR Part 820, and HIPAA Certification for Its PlatformWellthy Therapeutics completed FDA 21 CFR Part 11, Part 820, and HIPAA certifications for its modular SaMD platform, supporting its US expansion. The platform is also compliant with EU MDR, ISO, and GDPR standards, and has served over 150,000 patients.GlobeNewswireWellthy Extends Global Footprint, Appoints Veteran Commercial LeaderWellthy Therapeutics appointed Theo Ahadome as Chief Business Officer to drive global growth. The company reports 15 partnered solutions, over 100,000 patients, and 2,000 prescribing physicians. Ahadome previously led commercial at Happify Health and held roles at Science 37 and Amgen.